Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uliledlimab + Atezolizumab in Advanced Cancer
NCT03835949Phase 1Unknown
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of uliledlimab in solid tumor (advanced stage) and metastatic cancer, sponsored by TRACON Pharmaceuticals, Inc. Primary endpoint: Maximum Tolerated Dose of TJ004309 plus Atezolizumab. Status: unknown.
02
Drugs
uliledlimab
03
Conditions
solid tumor (advanced stage)metastatic cancer
Beyond the preview
Go deeper on NCT03835949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835949.